The FDA's Approval of the First mRNA Flu Vaccine for Older Adults Marks a New Chapter in Influenza Prevention The US Food and Drug Administration (FDA) has approved Moderna's mFLUSIVA vaccine, a crucial development for older adults seeking protection against seasonal influenza.
This approval raises questions about the agency's earlier stance on mRNA flu shots. At the heart of this story is a narrative of bureaucratic backpedaling and public health politics.
The FDA initially rejected Moderna's request to review its mRNA flu vaccine in February, citing concerns about the control flu vaccine used in the trial. Dr.